CD274 and neoplasm: Although anti–PD-L1 antibody (aPD-L1) is typically administrated for cancer immunotherapy, aPD-L1 usually suffers from poor diffusion, low tumor penetration, and immune-related adverse events, including fatal myocarditis, colitis, vitiligo, etc. (32, 33).